Welcome to our dedicated page for Biomark Diagnostics news (Ticker: BMKDF), a resource for investors and traders seeking the latest updates and insights on Biomark Diagnostics stock.
BioMark Diagnostics Inc. (BMKDF) is a pioneering developer of liquid biopsy solutions using metabolomics and machine learning for early cancer detection. This page serves as the definitive source for verified corporate news, research breakthroughs, and regulatory developments.
Investors and researchers will find timely updates on clinical trial progress, intellectual property expansions, and strategic collaborations with leading medical institutions. Our curated collection includes press releases on assay validations, peer-reviewed study publications, and conference participation details.
The news archive features essential updates across three key areas: 1) Technology advancements in blood-based cancer detection platforms, 2) Regulatory and IP developments including recent USPTO patent grants, and 3) Clinical research milestones demonstrating diagnostic accuracy across multiple cancer types. All content is sourced directly from company filings and authorized communications.
Bookmark this page for streamlined access to BMKDF's latest scientific achievements and corporate announcements. For comprehensive analysis of how these developments impact the oncology diagnostics sector, consult our regularly updated research library.
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a developer of liquid biopsy tests for early cancer detection, will participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9-11, 2024. CEO Rashid Bux and CSO Jean-François Haince will showcase BioMark's pipeline of liquid biopsy tests for lung cancer, breast cancer, and glioblastoma.
The company's presentation will be available on-demand through the conference portal on September 9, 2024, at 7:00 a.m. Eastern Time. BioMark will also conduct one-on-one meetings virtually. This event provides an opportunity for BioMark to connect with potential investors, partners, and industry experts as they prepare for the commercial launch of their early lung cancer assay and U.S. market entry.
BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTC Pink: BMKDF) has been granted U.S. Patent No. 17/895.69 by the USPTO, strengthening its liquid biopsy technology for cancer management. The patent protects BioMark's SAT1 legacy assay platform for assessing tumor velocity and treatment response in glioblastoma (GBM) and triple-negative breast cancer (TNBC) patients with specific genetic mutations.
Key points:
- GBM market size estimated at $2.80 billion in 2024, expected to reach $4.60 billion by 2029 (CAGR 8%)
- TNBC accounts for 15% of all breast cancers
- BioMark plans to launch a preclinical study for TNBC patients with BRCA mutations
- The patent enhances BioMark's position in developing cancer management solutions
BioMark Diagnostics Inc. (CSE: BUX) (OTC Pink: BMKDF) announced that collaborators from the University of Manitoba will present new research findings on glioblastoma at the 2024 GPEN Conference in Copenhagen. The presentations focus on:
1. Evaluation of hydrogel formulations for delivering siRNA to glioblastoma tumor cells
2. Examination of potential drug biomarker candidates for glioblastoma
The research highlights BioMark's liquid biopsy technology for evaluating minimal residual disease and treatment outcomes in glioblastoma. CEO Rashid Ahmed Bux emphasized their comprehensive approach, including biomarker discovery, novel drug delivery mechanisms, and potential gene knockdown treatments for glioblastoma.
FAQ
What is the current stock price of Biomark Diagnostics (BMKDF)?
What is the market cap of Biomark Diagnostics (BMKDF)?
